The VeriTac-2 trial assessed vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2* ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Extended follow-up data from the CheckMate 274 trial have further solidified adjuvant nivolumab’s position as a standard of ...

Arvinas and Pfizer have filed for U.S. Food and Drug Administration approval of their proposed breast-cancer drug vepdegestrant in certain patients with estrogen-receptor mutations.

Results from the Phase III VERITAC-2 trial demonstrated that vepdegestrant reduced the risk of disease progression or death ...

Fintel reports that on June 2, 2025, Leerink Partners downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Outperform to ...

While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...

Antibody drugs that target the PD-1 and VEGF pathways are in the ASCO spotlight, while doctors wrestle with how to use new ...

H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...

Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...

The US workforce is facing significant job cuts in June 2025, following widespread layoffs in the first quarter. Reports ...